PF-08046032

N/A

Report date: 2026/05/09 20:00:18

Base Information

Drug NamePF-08046032

Drug Alias NamePF-08046032

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payload

Mechanisms of ActionAnti-IL2RATubulin polymerisation inhibitors

TargetsInterleukin-2 receptor alpha chainTubulin

Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungSquamous Cell Carcinoma of Head and NeckMelanoma +[7]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesSpain

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesPfizer Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesPfizer Inc

Active IndicationsN/A

Inactive IndicationsCarcinoma, Non-Small-Cell LungSquamous Cell Carcinoma of Head and NeckMelanoma +[7]

Other Information

ATC CodeN/A